Integration of Circulating Tumor DNA and Metabolic Parameters on 18 F‐Fludeoxyglucose Positron Emission Tomography for Outcome Prediction in Unresectable Locally Advanced Non‐Small Cell Lung Cancer
Advanced Science · 2025
DOI: 10.1002/advs.202413125 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Leilei Wu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Circulating Tumor DNA, Lung Neoplasms, Fluorodeoxyglucose F18. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Talent Introduction Program of Shanghai Pulmonary Hospital, National Natural Science Foundation of China, Development Funds of the Department of Radiotherapy.
Abstract (Originalsprache)
This prospective study explores the prognostic value of circulating tumor DNA (ctDNA) and positron emission tomography/computed tomograpy (PET/CT) in unresectable locally advanced non‐small cell lung cancer (LA‐NSCLC) treated with definitive chemoradiotherapy (CRT). The discovery set includes 62 patients, with 62 baseline and 53 post‐CRT plasma samples. PET/CT is performed at baseline, and 33 patients undergo mid‐treatment scans after 40 Gy. Baseline ctDNA is detected in 71.0% of patients. Pre‐treatment ctDNA concentration correlates with total metabolic tumor volume (TMTV) ( p < 0.001) and total lesion glycolysis (TLG) ( p = 0.001) but not treatment response or survival. However, patients with undetectable ctDNA and low TMTV show significantly longer progression‐free survival (PFS) (34.2 vs 10.1 months, p = 0.027). Post‐CRT, ctDNA is detected in 47.2% of patients, while ctDNA concentration ( p = 0.005) and variant allele frequency (VAF) ( p = 0.005) significantly decline. Undetectable post‐CRT ctDNA associates with longer PFS ( p < 0.001) and overall survival (OS) ( p = 0.001). Higher ∆TMTV correlates with improved PFS and OS. Similar findings were obtained in a test of 19 patients. These results highlight post‐CRT ctDNA and ∆TMTV as robust prognostic markers, potentially identifying patients who may forgo ICI consolidation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
- Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.
- Department of Radiation Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui, 230031, China.
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, China.
- Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
ORCID-Profile: Leilei Wu, Zhenshan Zhang, Yaping Xu
Förderung
- Talent Introduction Program of Shanghai Pulmonary Hospital
- National Natural Science Foundation of China
- Development Funds of the Department of Radiotherapy
- Science and Technology Innovation Action Plan of the Science and Technology Commission of Shanghai Municipality
- Technical Standards Project of the Science and Technology Commission of Shanghai Municipality
- Hospital-level Key Project of Shanghai Pulmonary Hospital
- National Science Foundation for Distinguished Young Scholars of China
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Wu, L., Zhang, Z., Jiang, C., Li, L., Sun, X., Bai, M., Liu, M., Xiong, K., Shang, J., Yu, J., Yuan, S., Yang, Y., & Xu, Y. (2025). Integration of Circulating Tumor DNA and Metabolic Parameters on 18 F‐Fludeoxyglucose Positron Emission Tomography for Outcome Prediction in Unresectable Locally Advanced Non‐Small Cell Lung Cancer. Advanced Science. https://doi.org/10.1002/advs.202413125
Vancouver
Wu L, Zhang Z, Jiang C, Li L, Sun X, Bai M, et al. Integration of Circulating Tumor DNA and Metabolic Parameters on 18 F‐Fludeoxyglucose Positron Emission Tomography for Outcome Prediction in Unresectable Locally Advanced Non‐Small Cell Lung Cancer. Advanced Science. 2025. doi:10.1002/advs.202413125
BibTeX
@article{Wu2025,
author = {Wu, Leilei and Zhang, Zhenshan and Jiang, Chenxue and Li, Li and Sun, Xiaojiang and Bai, Menglin and Liu, Ming and Xiong, Kangli and Shang, Jinbiao and Yu, Jinming and Yuan, Shuanghu and Yang, Yang and Xu, Yaping},
title = {Integration of Circulating Tumor DNA and Metabolic Parameters on 18 F‐Fludeoxyglucose Positron Emission Tomography for Outcome Prediction in Unresectable Locally Advanced Non‐Small Cell Lung Cancer},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202413125}
}
EUVIMED